Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum‐based regimens
Open Access
- 1 March 2011
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 18 (5) , 350-357
Abstract
Objectives: We investigated the outcomes of paclitaxel and cisplatin chemotherapy as an optional regimen for patients with metastatic urothelial carcinoma after failure of two consecutive platinum‐based regimens.Methods: We retrospectively analyzed the data of 21 patients who had evidence of disease progression after two consecutive platinum‐based regimens, gemcitabine and cisplatin (GC course), and methotrexate, vinblastine, doxorubicin and cisplatin (M‐VAC course) as first‐line and second‐line treatments. As third‐line chemotherapy, patients received paclitaxel (175 mg/m2) and cisplatin (70 mg/m2) every 3 weeks until disease progression.Results: Complete remission occurred in one patient (4.8%), partial remission occurred in three patients (14.3%) and stable disease occurred in five patients (23.8%). The overall response rate was 19.0% and the overall disease control rate, including stable disease, was 42.9%. The median progression‐free survival (PFS) was 3 months (95% CI 3.0–5.0). The median overall survival was 9 months (95% CI 7.0–15.0). Grade 3 to 4 neutropenia appeared in 85.7% of patients. No life‐threatening complications were observed.Conclusions: Paclitaxel and cisplatin chemotherapy could be an optional regimen for patients with metastatic urothelial carcinoma after the failure of two consecutive standard platinum‐based regimens.Keywords
This publication has 22 references indexed in Scilit:
- Second-line therapy in bladder cancerCurrent Opinion in Urology, 2009
- Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial CarcinomaJapanese Journal of Clinical Oncology, 2009
- Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the BladderJournal of Urology, 2008
- Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapyBritish Journal of Cancer, 2007
- Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese casesInternational Journal of Urology, 2007
- Systemic therapy in metastatic or recurrent endometrial cancerCancer Treatment Reviews, 2007
- Systemic Chemotherapy for Advanced Bladder Cancer: Update and ControversiesJournal of Clinical Oncology, 2006
- Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinomaCancer, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000